Travere Therapeutics Earns Buy Rating from HC Wainwright

Analysts see upside potential after FDA approval expands addressable market for rare kidney disease drug

Apr. 16, 2026 at 6:06am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic banking machinery and mechanisms, conveying a sense of financial security, institutional strength, and stored wealth without depicting literal currency or charts.As Travere Therapeutics expands its rare disease drug portfolio, the company's financial infrastructure and institutional backing signal growing confidence in its ability to deliver long-term value.San Diego Today

Travere Therapeutics (NASDAQ:TVTX) had its 'buy' rating reiterated by HC Wainwright, with a $47 price target indicating potential upside of nearly 15% from the stock's previous close. The positive sentiment comes after the FDA granted full approval for Travere's Filspari drug to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disease, expanding the company's addressable market by an estimated 30,000 patients in the U.S.

Why it matters

The FDA approval and analyst upgrades signal increased confidence in Travere's ability to drive revenue growth through Filspari, a first-in-class treatment for FSGS. This rare kidney disease affects a small patient population, but the full approval and premium pricing potential could translate to material sales and earnings upside for the company over the coming years.

The details

Multiple brokerages raised their ratings and price targets on Travere following the Filspari approval, with Canaccord lifting its target to $56, Guggenheim to $54, and Piper Sandler to $49. The market reacted strongly to the news, with Travere's shares jumping around 37% as investors priced in the first-mover status, premium pricing, and volume-driven revenue growth potential for Filspari. However, some analysts caution that recent earnings estimate revisions may limit further near-term upside, and the heavy short-term speculative trading could lead to volatility or a pullback.

  • The FDA granted full approval for Filspari to treat FSGS on April 16, 2026.
  • Travere's stock price jumped approximately 37% on the approval news.

The players

Travere Therapeutics

A biopharmaceutical company headquartered in San Diego, California, dedicated to developing and commercializing therapies for rare kidney and genetic disorders.

HC Wainwright

An investment banking firm that reiterated its 'buy' rating and $47 price target on Travere Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.